NEW DELHI: In a major push for the war against Covid-19, Britain on Wednesday authorized the emergency use of the Oxford-AstraZeneca vaccine, becoming the first country to approve the vaccine that is expected to be the mainstay of the program. inoculation from India in early 2021.
The Indian regulator is expected to do the same soon, but the committee of subject matter experts that met on Wednesday sought more data related to the immunogenicity of the vaccine, which will mean that approval for emergency use may take a few more days. . The committee will meet next Friday, raising hopes for a vaccine launch in early January.
The committee will review the updated data submitted by the Serum Institute of India and also the indigenous vaccine candidate from Bharat Biotech. IBS has said it has already stocked 40 to 50 million injections of Covishield and is increasing this number every week.
Reports say that Covishield could become the most widely used injection given its moderate price of $ 3- $ 4 per dose and that it can be transported and stored in normal refrigerators for several weeks.
Pfizer-BioNTech requires freezers at minus 70 °, while Moderna requires minus 20 °, and both cost more. The UK authorities have decided to opt to give as many individual injections as possible with the interval between injections set at 4-12 weeks in an attempt to reach the wider population. The plan is based on Covishield shots reporting increased effectiveness at extended intervals.
Regarding India’s assessment, one official said: “The committee has to review the data on the basis of which the company has received UK approval. In a situation like this, the regulator will have to ensure that the data sent in India is correlated with the global data. “” The additional data submitted by SII and Bharat Biotech was examined and analyzed by the SEC. The analysis of the data and additional information is ongoing. The SEC will meet again on January 1, “the government said.
Events indicate that India’s vaccination campaign will be implemented in early January, aiming to inoculate around 30 million people in the first phase by July.
The OAZ vaccine becomes the second vaccine licensed for use in the UK after the Pfizer-BioNTech vaccine became the world’s first to be licensed on December 2. The UK government has reserved 100 million doses, enough to vaccinate 50 million people. in a two-shot regime. This would cover the entire UK population, when combined with the Pfizer vaccine.
The UK regulator recommends two standard doses 4 to 12 weeks apart of the Oxford vaccine, which will provide 70% efficacy. “Some people received second doses at different time intervals and it showed that the effectiveness was high, up to 80%, when there was an interval of three months,” explained Sir Munir Pirmohamed, chairman of the expert working group of the Medical Commission. Human
The Indian regulator is expected to do the same soon, but the committee of subject matter experts that met on Wednesday sought more data related to the immunogenicity of the vaccine, which will mean that approval for emergency use may take a few more days. . The committee will meet next Friday, raising hopes for a vaccine launch in early January.
The committee will review the updated data submitted by the Serum Institute of India and also the indigenous vaccine candidate from Bharat Biotech. IBS has said it has already stocked 40 to 50 million injections of Covishield and is increasing this number every week.
Reports say that Covishield could become the most widely used injection given its moderate price of $ 3- $ 4 per dose and that it can be transported and stored in normal refrigerators for several weeks.
Pfizer-BioNTech requires freezers at minus 70 °, while Moderna requires minus 20 °, and both cost more. The UK authorities have decided to opt to give as many individual injections as possible with the interval between injections set at 4-12 weeks in an attempt to reach the wider population. The plan is based on Covishield shots reporting increased effectiveness at extended intervals.
Regarding India’s assessment, one official said: “The committee has to review the data on the basis of which the company has received UK approval. In a situation like this, the regulator will have to ensure that the data sent in India is correlated with the global data. “” The additional data submitted by SII and Bharat Biotech was examined and analyzed by the SEC. The analysis of the data and additional information is ongoing. The SEC will meet again on January 1, “the government said.
Events indicate that India’s vaccination campaign will be implemented in early January, aiming to inoculate around 30 million people in the first phase by July.
The OAZ vaccine becomes the second vaccine licensed for use in the UK after the Pfizer-BioNTech vaccine became the world’s first to be licensed on December 2. The UK government has reserved 100 million doses, enough to vaccinate 50 million people. in a two-shot regime. This would cover the entire UK population, when combined with the Pfizer vaccine.
The UK regulator recommends two standard doses 4 to 12 weeks apart of the Oxford vaccine, which will provide 70% efficacy. “Some people received second doses at different time intervals and it showed that the effectiveness was high, up to 80%, when there was an interval of three months,” explained Sir Munir Pirmohamed, chairman of the expert working group of the Medical Commission. Human
.
